Shir Beauty & Science

Vendor Biography

Innocan Pharma is a pharmaceutical technology company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprised of cannabinoids science to treat various conditions and improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform, which facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; and (ii) CLX CBD-loaded exosomes platform, which aims to target the central nervous system through regeneration and by addressing inflammation. In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative self-care products to promote a healthier lifestyle. Under this segment Innocan has established a joint venture by the name of BI Sky Global Ltd., which focuses on developing advanced targeted online sales.

Innocan Pharma is led by a multi-disciplinary management and R&D team, headed by: Iris Bincovich, an experienced healthcare Executive, Ron Mayron, former CEO of Teva Israel, one of the largest generic pharmaceutical companies in the world. Prof. Chezy Barenholz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem and Prof. Daniel Offen, a leading researcher specializing in Neuroscience and Exosome technology, Head of the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University,
Antonio Benitz, Animal Health R&D Advisor Global Head of R&D at Novartis Animal Health and VP R&D at Pfizer Animal Health. Former senior executive at Merial and Merck.
Dr. Jospeh Pergolizzi, has extensive academic, clinical, and business achievements related to his lifelong interest in advancing medical science and the practice of modern global healthcare.
Dr. Pergolizzi is a Senior Partner at Naples Anesthesia and Pain Associates and serves as the Chief Operating Officer at NEMA Research Inc. He is a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics and a Consultant to the National Pain Foundation Board of Directors.